Elanco Animal Health Inc (ELAN) Form 8-K — Aug 5, 2026
Elanco Animal Health reported second quarter 2026 revenue of $1,368 million, up 10% year over year (8% organic constant currency), with reported net income of $54 million, adjusted net income of $174 million, and adjusted EPS of $0.34, a 31% increase versus the prior-year quarter. Adjusted EBITDA rose 21% to $288 million with a 21.2% margin. Management raised full year 2026 guidance across the board: revenue to $5.09-$5.14 billion, adjusted EBITDA to $1.01-$1.035 billion, and adjusted EPS to $1.10-$1.16, while lifting the innovation revenue target to $1.25 billion. Third quarter guidance calls for revenue of $1,195-$1,220 million and adjusted EPS of $0.19-$0.22.
Key figures
- Eps
- 0.11
- Revenue
- 1368000000
- Guidance
- FY2026 guidance raised to revenue of $5,090-$5,140 million (6-7% organic constant currency growth), adjusted EBITDA of $1,010-$1,035 million (+13% YoY at midpoint), and adjusted EPS of $1.10-$1.16 (+20% YoY at midpoint); Q3 2026 guidance of revenue $1,195-$1,220 million, adjusted EBITDA $200-$215 million, adjusted EPS $0.19-$0.22; innovation revenue target raised to $1.25 billion.
- Net Income
- 54000000
- Total Debt
- 3944000000
- Revenue Yoy
- 10% reported; 8% organic constant currency
- Cash Position
- 530000000
- Net Debt
- 3159000000
- Adjusted Eps
- 0.34
- Gross Profit
- 798000000
- Adjusted Ebitda
- 288000000
- Adjusted Eps Yoy
- 31%
- Six Month Revenue
- 2739000000
- Net Leverage Ratio
- 3.1x adjusted EBITDA
- Pet Health Revenue
- 718000000
- Adjusted Net Income
- 174000000
- Farm Animal Revenue
- 633000000
- Six Month Net Income
- 111000000
- Fx Tailwind Full Year
- approximately $60 million
- Gross Margin Percent
- 58.3
- Operating Cash Flow Q2
- 277000000
- Six Month Adjusted Eps
- 0.75
- Adjusted Ebitda Margin
- 21.2%
- Prior Net Leverage Dec2025
- 3.6x (3.1x is a 0.5x decrease)
- Elanco Ascend Savings Target
- $200 million to $250 million in adjusted EBITDA net savings by 2030
- Trailing Twelve Month Adjusted Ebitda
- 1008000000
Price after filing
Close on the filing date to close N calendar days later (from $25.60). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.